Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT07265544 Sponsor: Nanfang Hospital, Southern Medical University Condition: Non-Alcoholic Fatty Liver Disease
Back to Non Alcoholic Fatty Liver Disease

Non-Alcoholic Fatty Liver Disease Trial, Recruiting

NCT07265544
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have voluntarily agreed to take part and signed a consent form
  • People of any age or gender are eligible to be considered
  • People who have been diagnosed with a liver haemangioma (a benign growth made up of blood vessels in the liver) or focal nodular hyperplasia (another type of non-cancerous liver growth), diagnosed according to recognised clinical guidelines
  • People who have a liver haemangioma, focal nodular hyperplasia, fatty liver, hepatitis B virus infection, liver scarring (fibrosis), or liver cirrhosis, and whose doctor has determined that liver surgery or a liver biopsy is clinically needed

Who may not be able to join:

  • People who currently have certain infections, such as HIV
  • People who have a blood clotting disorder, such as haemophilia or a condition where the immune system attacks platelets (confirm with trial site)
  • People who have serious underlying health conditions that affect how the immune system functions
  • People whom the trial investigator considers unsuitable for participation for any reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +8613826039505

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Nanfang Hospital, Southern Medical University
Registry
ClinicalTrials.gov
Start date
1 March 2023
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change From Control in Liver Inflammation Degree at Postoperative

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov